191 related articles for article (PubMed ID: 31615597)
1. Monitoring liver transplant rates in persons diagnosed with hepatitis C: a data linkage study, England 2008 to 2017.
Ireland G; Simmons R; Hickman M; Ramsay M; Sabin C; Mandal S
Euro Surveill; 2019 Oct; 24(41):. PubMed ID: 31615597
[TBL] [Abstract][Full Text] [Related]
2. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
4. Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016.
Ireland G; Mandal S; Hickman M; Ramsay M; Harris R; Simmons R
Euro Surveill; 2019 Jul; 24(30):. PubMed ID: 31362807
[TBL] [Abstract][Full Text] [Related]
5. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
[TBL] [Abstract][Full Text] [Related]
7. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
8. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
[TBL] [Abstract][Full Text] [Related]
9. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
[TBL] [Abstract][Full Text] [Related]
10. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
11. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.
Gidding HF; Topp L; Middleton M; Robinson K; Hellard M; McCaughan G; Maher L; Kaldor JM; Dore GJ; Law MG
J Gastroenterol Hepatol; 2009 Oct; 24(10):1648-54. PubMed ID: 19798783
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents.
Kyvernitakis A; Mahale P; Popat UR; Jiang Y; Hosry J; Champlin RE; Torres HA
Biol Blood Marrow Transplant; 2016 Apr; 22(4):717-722. PubMed ID: 26712592
[TBL] [Abstract][Full Text] [Related]
13. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
[TBL] [Abstract][Full Text] [Related]
15. The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
Younossi ZM; Stepanova M; Saab S; Ahmed A; Lam B; Srishord M; Venkatesan C; Wai H; Henry L
J Viral Hepat; 2016 Jan; 23(1):53-61. PubMed ID: 26289820
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis.
Sobotka LA; Mumtaz K; Wellner MR; Kelly SG; Conteh LF; Hanje AJ; Schenk A; El-Hinnawi A; Black S; Washburn K; Pesavento T; Daloul R; Michaels AJ
Ann Hepatol; 2021; 24():100318. PubMed ID: 33515801
[TBL] [Abstract][Full Text] [Related]
17. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
Tanaka T; Voigt MD
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series.
Campos-Varela I; Agudelo EZ; Terrault NA
Clin Transplant; 2018 Jul; 32(7):e13303. PubMed ID: 29851150
[TBL] [Abstract][Full Text] [Related]
20. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
